Celgene to Acquire Juno for $9 Billion, Picking Up Potential CAR T-cell Lymphoma Therapies – Lymphoma News Today
Lymphoma News Today |
Celgene to Acquire Juno for $9 Billion, Picking Up Potential CAR T-cell Lymphoma Therapies
Lymphoma News Today Celgene will buy Juno Therapeutics for $9 billion in a deal that gives Celgene access to an experimental gene therapy for treating people with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. The acquisition, announced Jan. 22 … Here's Why Fate Therapeutics Rose as Much as 18% Today |
